Zacks Investment Research lowered shares of Five Prime Therapeutics (NASDAQ:FPRX) from a hold rating to a sell rating in a research report released on Thursday morning, Zacks.com reports.

According to Zacks, “Five Prime Therapeutics, Inc. is a biotechnology company. The company focuses on the discovery and development of protein therapeutics that blocks cancer and inflammatory disease processes. It operates primarily in the United States and Canada. Five Prime Therapeutics, Inc. is based in San Francisco, California. “

Other analysts have also recently issued reports about the company. Roth Capital assumed coverage on Forty Seven in a report on Wednesday, May 29th. They set a buy rating and a $28.00 price objective on the stock. BidaskClub upgraded Winmark from a sell rating to a hold rating in a report on Tuesday, May 14th. Guggenheim lowered Anadarko Petroleum from a buy rating to a hold rating and set a $69.00 price target on the stock. in a report on Friday, April 12th. Wells Fargo & Co decreased their price target on Cummins from $175.00 to $165.00 and set a market perform rating on the stock in a report on Monday, June 3rd. Finally, ValuEngine lowered Zumiez from a hold rating to a sell rating in a report on Monday, May 13th. Three equities research analysts have rated the stock with a sell rating, two have given a hold rating and five have assigned a buy rating to the stock. The company currently has a consensus rating of Hold and a consensus target price of $20.00.

Shares of FPRX opened at $5.66 on Thursday. Five Prime Therapeutics has a 1 year low of $5.55 and a 1 year high of $17.80. The business’s 50 day moving average price is $6.69. The company has a debt-to-equity ratio of 0.21, a quick ratio of 10.41 and a current ratio of 10.41.

Five Prime Therapeutics (NASDAQ:FPRX) last issued its quarterly earnings data on Wednesday, May 8th. The biotechnology company reported ($1.02) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.07) by $0.05. The business had revenue of $5.35 million for the quarter, compared to analysts’ expectations of $5.71 million. Five Prime Therapeutics had a negative return on equity of 54.87% and a negative net margin of 683.89%. As a group, equities analysts forecast that Five Prime Therapeutics will post -3.67 EPS for the current fiscal year.

Large investors have recently added to or reduced their stakes in the stock. Northern Trust Corp grew its position in Five Prime Therapeutics by 0.5% in the 4th quarter. Northern Trust Corp now owns 425,775 shares of the biotechnology company’s stock valued at $3,959,000 after acquiring an additional 2,278 shares during the last quarter. Alps Advisors Inc. grew its position in Five Prime Therapeutics by 4.5% in the 1st quarter. Alps Advisors Inc. now owns 85,663 shares of the biotechnology company’s stock valued at $1,148,000 after acquiring an additional 3,707 shares during the last quarter. BNP Paribas Arbitrage SA grew its position in Five Prime Therapeutics by 1,929.9% in the 1st quarter. BNP Paribas Arbitrage SA now owns 7,328 shares of the biotechnology company’s stock valued at $98,000 after acquiring an additional 6,967 shares during the last quarter. Bailard Inc. bought a new position in Five Prime Therapeutics in the 1st quarter valued at $141,000. Finally, Metropolitan Life Insurance Co. NY grew its position in Five Prime Therapeutics by 456.2% in the 4th quarter. Metropolitan Life Insurance Co. NY now owns 13,283 shares of the biotechnology company’s stock valued at $124,000 after acquiring an additional 10,895 shares during the last quarter. Institutional investors own 86.91% of the company’s stock.

Five Prime Therapeutics Company Profile

Five Prime Therapeutics, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of innovative protein therapeutics. The company's product candidates comprise Bemarituzumab, an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, which is in Phase III clinical trials to treat patients with gastric or gastroesophageal junction and GEJ cancer; and FPA150, a CD8 T cell checkpoint inhibitor antibody that targets B7-H4 in various cancers, as well as FPT155, a soluble CD80 fusion protein that enhances co-stimulation of T cells through CD28.

See Also: What Does Beta Mean In Stock Selection

Get a free copy of the Zacks research report on Five Prime Therapeutics (FPRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Five Prime Therapeutics (NASDAQ:FPRX)

Receive News & Ratings for Five Prime Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.